Nicholas P. Restifo

From Wikipedia, the free encyclopedia
Nicholas P. Restifo
Born (1960-07-24) 24 July 1960 (age 61)
Columbus, Ohio
NationalityAmerican
EducationJohns Hopkins University,
New York University School of Medicine
OccupationImmunologist at the National Cancer Institute
Known forT cell-based immunotherapy

Nicholas P. Restifo (born July 24, 1960) is an American immunologist, physician and educator in cancer immunotherapy. Until July 2019, he was a tenured senior investigator in the intramural National Cancer Institute of the National Institutes of Health at Bethesda, Maryland.[1][self-published source?] Nicholas is now the executive vice president of research at Lyell based in San Francisco.

Dr. Restifo has been a pioneer in the use of T cell-based immunotherapy.

Early life and education[]

Dr. Restifo was born July 24, 1960 in Columbus, Ohio. He grew up in a small town, Amherst, Ohio, and went to high school in Lorain, Ohio. He completed his undergraduate education with honors at the Johns Hopkins University and obtained his medical degree from New York University School of Medicine. He first joined the National Cancer Institute, NIH in Bethesda, Maryland in 1989. He was recruited from the Memorial Sloan Kettering Cancer Center, where he worked in the laboratory of Murray Brennan, the former chairman of Surgery. He became a principal investigator [2] in 1993 and has authored or co-authored more than 300 papers and book chapters on cancer immunotherapy.[3]

Research[]

Dr. Restifo's most recent efforts include a focus on how elements – literally from the periodic table – influence cancer immunity. These include work on how oxygen can inhibit anti-tumor immunity [4] and how potassium ions from dying cancer cells can shut down the anti-tumor response.[5]

Successful treatment of patients with cancer is the goal of his laboratory, and his therapeutic approaches employ adoptive T cell transfer, gene modification and cellular reprogramming.[6] Basic aspects of tumor and T cell immunology inform novel therapeutic interventions in the clinic.

Restifo and his research team have made contributions to the fields of adoptive cell transfer[7] tumor immune-escape,[8][9] virally encoded cancer vaccines,[10] adoptive cell transfer for the treatment of cancer, and the biology of self/tumor-reactive T cells, with an emphasis on memory CD8+ T cells.[11]

See also[]

References[]

  1. ^ "Nicholas P. Restifo, M.D." National Cancer Institute. September 12, 2009. Archived from the original on March 24, 2010. Retrieved April 14, 2010.
  2. ^ https://ccr.cancer.gov/Surgery-Branch/nicholas-p-restifo?qt-staff_profile_tabs=3#qt-staff_profile_tabs
  3. ^ Search Results for author Restifo NP on PubMed.
  4. ^ Clever, D, et al. (Aug 25, 2016). "Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche". Cell. 166 (5): 1117–1131. doi:10.1016/j.cell.2016.07.032. PMC 5548538. PMID 27565342.
  5. ^ Eil, R, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016 Sep 14. doi: 10.1038/nature19364. [Epub ahead of print]
  6. ^ Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
  7. ^ Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
  8. ^ Restifo NP, Esquivel F, Kawakami Y, et al. (February 1993). "Identification of human cancers deficient in antigen processing". The Journal of Experimental Medicine. 177 (2): 265–72. doi:10.1084/jem.177.2.265. PMC 1950463. PMID 8426105.
  9. ^ Khong HT, Restifo NP (November 2002). "Natural selection of tumor variants in the generation of "tumor escape" phenotypes". Nature Immunology. 3 (11): 999–1005. doi:10.1038/ni1102-999. PMC 1508168. PMID 12407407.
  10. ^ Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP (May 1995). "Synthetic Oligonucleotide Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic CTL". Journal of Immunology. 154 (9): 4651–7. PMC 1976247. PMID 7722317.
  11. ^ Gattinoni, Luca; Zhong, Xiao-Song; Palmer, Douglas C; Ji, Yun; Hinrichs, Christian S; Yu, Zhiya; Wrzesinski, Claudia; Boni, Andrea; Cassard, Lydie; Garvin, Lindsay M; Paulos, Chrystal M; Muranski, Pawel; Restifo, Nicholas P (July 2009). "Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells". Nature Medicine. 15 (7): 808–13. doi:10.1038/nm.1982. PMC 2707501. PMID 19525962. Lay summary – EmaxHealth (June 15, 2009). {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
Retrieved from ""